Xilio Therapeutics, Inc.XLONASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank100
3Y CAGR+212.2%
Studio
Year-over-Year Change

Price-to-book ratio

3Y CAGR
+212.2%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
30.4x
Strong expansion
Streak
2 yr
Consecutive growthElevated
PeriodValueYoY Change
202521.23+631.2%
20242.90+607.2%
20230.41-41.1%
20220.70+44.2%
20210.48+130.5%
2020-1.59-1032.5%
20190.17-